Research programme: neoantigen-based cancer immunotherapeutics - Gritstone Oncology/Immune Design

Drug Profile

Research programme: neoantigen-based cancer immunotherapeutics - Gritstone Oncology/Immune Design

Alternative Names: ChAdV-srRNA based TSNA vaccine; multi-genome ZVex; ZVex-Neo; ZVexMulti

Latest Information Update: 11 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gritstone Oncology; Immune Design
  • Developer Gritstone Oncology
  • Class Antineoplastics; Cancer vaccines; Immunoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 07 May 2018 Gritstone Oncology receives patent allowance for its EDGE™ technology in USA
  • 07 May 2018 Gritstone Oncology expects to submit IND application for clinical development in Cancer in the second half of 2018
  • 12 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer released by Gritstone Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top